Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 801–900 of 1,018
Modern Management of Acute Myocardial Infarction
Yang, E. H., Brilakis, E. S., Reeder, G. S., & Gersh, B. J. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.08.004 · Cited by 87
Sabbah, H. N., Imai, M., Cowart, D., Amato, A., Carminati, P., & Gheorghiade, M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.09.005 · Cited by 76
Pandey, A., Garg, S. K., Matulevicius, S. A., Shah, A. M., Garg, J., Drazner, M. H., Amin, A., Berry, J. D., Marwick, T. H., Marso, S. P., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002137 · Cited by 82
Martinerie, L., Munier, M., Menuet, D. L., Méduri, G., Viengchareun, S., & Lombès, M. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.030 · Cited by 78
How robust are clinical trials in heart failure?
Docherty, K. F., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw427 · Cited by 83
Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery
Boulet, J., & Mehra, M. R. (2021) · Structural Heart · doi:10.1080/24748706.2021.1954275 · Cited by 85
Edwards, N. C., Steeds, R. P., Chue, C. D., Stewart, P. M., Ferro, C. J., & Townend, J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04102.x · Cited by 81
Do we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros, V. G., Kakafika, A. I., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.026 · Cited by 81
Huang, W. G., Chen, X., Kahng, K. W., Noble, N. A., Border, W. A., & Huang, Y. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00017.2008 · Cited by 75
Marzolla, V., Armani, A., Feraco, A., Martino, M. U. D., Fabbri, A., Rosano, G. M. C., & Caprio, M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.001 · Cited by 79
Aldosterone Antagonism in Chronic Kidney Disease
Ponda, M. P., & Hostetter, T. H. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00120106 · Cited by 75
Salt Excess Causes Left Ventricular Diastolic Dysfunction in Rats With Metabolic Disorder
Matsui, H., Ando, K., Kawarazaki, H., Nagae, A., Fujita, M., Shimosawa, T., Nagase, M., & Fujita, T. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.111815 · Cited by 75
Mazurek, J. A., & Jessup, M. L. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.001 · Cited by 92
The Role of Aldosteronism in Causing Obesity-Related Cardiovascular Risk
Calhoun, D. A., & Sharma, K. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.04.001 · Cited by 74
Edelmann, F., Schmidt, A. G., Gelbrich, G., Binder, L., Herrmann‐Lingen, C., Halle, M., Hasenfuss, G. P., Wachter, R., & Pieske, B. M. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq087 · Cited by 79
Lv, R., Xu, L., Che, L., Liu, S., Wang, Y., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125693 · Cited by 80
Primary aldosteronism: current knowledge and controversies in Conn's syndrome
Schirpenbach, C., & Reincke, M. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0430 · Cited by 87
Ambroisine, M.-L., Favre, J., Oliviéro, P., Rodriguez, C., Gao, J., Thuillez, C., Samuel, J., Richard, V. J., & Delcayre, C. (2007) · Circulation · doi:10.1161/circulationaha.107.722009 · Cited by 74
Nakamura, T., Kataoka, K., Fukuda, M., Nako, H., Tokutomi, Y., Dong, Y.-F., Ichijo, H., Ogawa, H., & Kim-Mitsuyama, S. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.135392 · Cited by 74
McMurray, J. J. V., Pfeffer, M. A., Swedberg, K. B., & Dzau, V. J. (2004) · Circulation · doi:10.1161/01.cir.0000147274.83071.68 · Cited by 80
Drummond, H. A., Jernigan, N. L., & Grifoni, S. C. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.093401 · Cited by 74
Go, A. S., Yang, J., Gurwitz, J. H., Hsu, J., Lane, K., & Platt, R. G. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.506 · Cited by 78
Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis
Young, M. J., & Rickard, A. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.008 · Cited by 77
Lucas, S., Heim, R., Negri, M., Antes, I., Ries, C., Schewe, K. E., Bisi, A., Gobbi, S., & Hartmann, R. W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800683c · Cited by 73
A review of heart failure management in the elderly population
Cheng, J. W. M., & Nayar, M. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.10.001 · Cited by 78
Kanashiro‐Takeuchi, R. M., Heidecker, B., Lamirault, G., Dharamsi, J. W., & Hare, J. M. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00094.x · Cited by 73
Heinig, R., Kimmeskamp‐Kirschbaum, N., Halabi, A., & Lentini, S. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.263 · Cited by 70
Sommer, J. C., Seeling, A., & Rupprecht, H. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00747-0 · Cited by 83
Jessup, M. L., Banner, N. R., Brozena, S. C., Campana, C., Costard‐Jäckle, A., Dengler, T. J., Hunt, S. A., Metra, M., Rahmel, A. O., Renlund, D. G., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.06.007 · Cited by 76
Diuretics and Bone Loss in Rats With Aldosteronism
Law, P., Sun, Y., Bhattacharya, S. K., Chhokar, V. S., & Weber, K. T. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.055 · Cited by 75
Future treatment strategies in ST-segment elevation myocardial infarction
Windecker, S., Bax, J. J., Myat, A., Stone, G. W., & Marber, M. S. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61452-x · Cited by 78
Conditional glucocorticoid receptor expression in the heart induces atrio‐ventricular block
Sainte–Marie, Y., Cat, A. N. D., Perrier, R., Mangin, L., Soukaseum, C., Peuchmaur, M. M., Tronche, F., Farman, N., Escoubet, B., Bénitah, J., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8357com · Cited by 74
Enfermedad cardiovascular en el anciano
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.001 · Cited by 95
Endothelial cells as vascular salt sensors
Oberleithner, H., Kusche‐Vihrog, K., & Schillers, H. (2010) · Kidney International · doi:10.1038/ki.2009.490 · Cited by 72
Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome
Tirosh, A., Garg, R., & Adler, G. K. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0126-2 · Cited by 71
Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
Sabbadin, C., Bordin, L., Donà, G., Manso, J., Avruscio, G., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00484 · Cited by 72
Rakugi, H., Ito, S., Itoh, H., Okuda, Y., & Yamakawa, S. (2019) · Hypertension Research · doi:10.1038/s41440-019-0314-7 · Cited by 73
Heart failure as a substrate and trigger for ventricular tachycardia
Alvarez, C., Cronin, E. M., Baker, W. L., & Kluger, J. (2019) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-019-00623-x · Cited by 74
Brown, J., de Boer, I. H., Robinson-Cohen, C., Siscovick, D. S., Kestenbaum, B., Allison, M., & Vaidya, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3949 · Cited by 71
LISTER, K., Autelitano, D. J., Jenkins, A. J., Hannan, R. D., & Sheppard, K. E. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.02.010 · Cited by 75
Recovery from ischemic acute kidney injury by spironolactone administration
Sanchez-Pozos, K. A., Barrera‐Chimal, J., Garzon-Muvdi, J., Pérez‐Villalva, R., Rodríguez‐Romo, R., Cruz, C., Gamba, G., & Bobadilla, N. A. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs014 · Cited by 72
Aldosterone as a modulator of immunity: implications in the organ damage
Herrada, A. A., Campino, C., Amador, C. A., Michea, L., Fardella, C., & Kalergis, A. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834a4c75 · Cited by 75
Lucas, S., Negri, M., Heim, R., Zimmer, C., & Hartmann, R. W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101470k · Cited by 75
Genomic and rapid effects of aldosterone: what we know and do not know thus far
Hermidorff, M. M., de Assis, L. V. M., & Isoldi, M. C. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9591-2 · Cited by 75
Understanding acute heart failure: pathophysiology and diagnosis
Arrigo, M., Parissis, J., Akiyama, E., & Mebazaa, A. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw044 · Cited by 86
O’Keefe, J. H., Abuissa, H., & Pitt, B. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00730.x · Cited by 71
Self-citationJCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
Nakamura, M., Yaku, H., Ako, J., Arai, H., Asai, T., Chikamori, T., Daida, H., Doi, K., Fukui, T., Ito, T., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.1253/circj.cj-20-1282 · Cited by 70
Hobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Kim, S., Kwon, J., Jones, L., Hirst, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03263-5 · Cited by 76
Luther, J. M., Luo, P., Wang, Z., Cohen, S. E., Kim, H.-S., Fogo, A. B., & Brown, N. J. (2012) · Kidney International · doi:10.1038/ki.2012.170 · Cited by 69
Andersen, K., Hartman, D., Peppard, T., Hermann, D., Van Ess, P., Lefkowitz, M., & Trapani, A. (2012) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00667.x · Cited by 68
Different Somatic Mutations in Multinodular Adrenals With Aldosterone-Producing Adenoma
Fernandes-Rosa, F. L., Giscos-Douriez, I., Amar, L., Gómez-Sánchez, C. E., Méatchi, T., Boulkroun, S., & Zennaro, M. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05993 · Cited by 70
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes
Szummer, K. E., Jernberg, T., & Wallentin, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.531 · Cited by 77
Schürmann, R., Holler, T., & Benda, N. (2004) · Climacteric · doi:10.1080/13697130410001713698 · Cited by 69
Heart Failure Subtypes and Cardiomyopathies in Women
DeFilippis, E. M., Beale, A., Martyn, T., Agarwal, A., Elkayam, U., Lam, C. S. P., & Hsich, E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319900 · Cited by 77
Aldosterone and cardiovascular diseases
Parksook, W. W., & Williams, G. H. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac027 · Cited by 72
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Kim, D., Lee, S., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1629 · Cited by 73
Michel, A., Martín‐Pérez, M., Ruigómez, A., & Rodríguez, L. A. G. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.226 · Cited by 72
CXCR4 Antagonism Attenuates the Cardiorenal Consequences of Mineralocorticoid Excess
Chu, P.-Y., Zatta, A., Kiriazis, H., Chin-Dusting, J., Du, X.-J., Marshall, T., & Kaye, D. M. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.960831 · Cited by 70
A direct relationship between plasma aldosterone and cardiac L‐type Ca2+ current in mice
Perrier, R., Richard, S., Sainte–Marie, Y., Rossier, B. C., Jaisser, F., Hümmler, E., & Bénitah, J. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.092692 · Cited by 76
Pathophysiology of Heart Failure
Mann, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00025-1 · Cited by 84
Schelbert, E. B., Sabbah, H. N., Butler, J., & Gheorghiade, M. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005619 · Cited by 71
Yaku, H., Kato, T., Morimoto, T., Inuzuka, Y., Tamaki, Y., Ozasa, N., Yamamoto, E., Yoshikawa, Y., Kitai, T., Taniguchi, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.5892 · Cited by 70
An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome
Raina, R., Nair, N., Chakraborty, R., Nemer, L., Dasgupta, R., & Varian, K. D. (2020) · Cardiology Research · doi:10.14740/cr955 · Cited by 76
Structure and function of coagulogen, a clottable protein in horseshoe crabs
Osaki, T., & Kawabata, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3396-5 · Cited by 69
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman, T. J., Baranowski, B. J., Ashen, M. D., Henrikson, C. A., McAllister, M. W., Braunstein, J. B., & Blumenthal, R. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1490 · Cited by 73
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 76
Brieger, D. B., Cullen, L., Briffa, T. G., Zaman, S. J., Scott, I. A., Papendick, C., Bardsley, K., Baumann, A. A. W., Bennett, A., Clark, R. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.02.102 · Cited by 74
Kjeldsen, S. E. (2004) · Heart Drug · doi:10.1159/000076262 · Cited by 71
Lainščak, M., Cleland, J. G. F., Lenzen, M. J., Folláth, F., Komajda, M., & Swedberg, K. B. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.07.007 · Cited by 73
Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?
Weir, R. A. P., Mark, P. B., Petrie, C. J., Clements, S. E., Steedman, T., Ford, I., Ng, L. L., Squire, I. B., Wagner, G. S., McMurray, J. J. V., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.04.001 · Cited by 68
Habibi, J., DeMarco, V. G., Ma, L., Pulakat, L., Rainey, W. E., Whaley‐Connell, A. T., & Sowers, J. R. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01000.2010 · Cited by 69
Lentini, S., Heinig, R., Kimmeskamp‐Kirschbaum, N., & Wensing, G. (2016) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12170 · Cited by 63
Orsborne, C., Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134045 · Cited by 79
Aldosterone and Cardiovascular Disease
Gaddam, K. K., Pimenta, E., Husain, S., & Calhoun, D. A. (2009) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2008.10.002 · Cited by 76
Geller, D. S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02229.x · Cited by 72
Collins, P., Rosano, G., Casey, C., Daly, C., Gambacciani, M., Hadji, P., Kaaja, R., Mikkola, T., Palacios, S., Preston, R., et al. (2007) · Climacteric · doi:10.1080/13697130701755213 · Cited by 67
Girerd, N., Pang, P. S., Swedberg, K. B., Fought, A. J., Kwasny, M., Subacius, H. P., Konstam, M. A., Maggioni, A. P., Gheorghiade, M., Zannad, F. M., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft100 · Cited by 67
Self-citationLoh, J. C., Creaser, J. W., Rourke, D., Livingston, N., Harrison, T. K., Vandenbogaart, E., Moriguchi, J. D., Hamilton, M. A., Tseng, C., Fonarow, G. C., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000178 · Cited by 67
The Safety of Eplerenone in Hemodialysis Patients
Walsh, M. W., Manns, B., Garg, A. X., Bueti, J., Rabbat, C. G., Smyth, A., Tyrwhitt, J., Bosch, J., Gao, P., Devereaux, P. J., et al. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12371214 · Cited by 68
Cannavò, A., Liccardo, D., Eguchi, A., Elliott, K. J., Traynham, C. J., Ibetti, J., Eguchi, S., Leosco, D., Ferrara, N., Rengo, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10877 · Cited by 67
Lakkis, J. I., Lu, W. X., & Weir, M. R. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0087-9 · Cited by 68
Svensson, M., Gustafsson, F., Galatius, S., Hildebrandt, P. R., & Atar, D. (2003) · BMJ · doi:10.1136/bmj.327.7424.1141 · Cited by 67
Bell, D. S. H., Ann Lukas, M., Holdbrook, F. K., & Fowler, M. B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80459 · Cited by 66
Tromp, J., Ouwerkerk, W., Teng, T. K., Cleland, J. G. F., Bamadhaj, S., Angermann, C. E., Dahlström, U., Tay, W. T., Dickstein, K., Ertl, G., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac103 · Cited by 67
Brown, J. M., Wijkman, M. O., Claggett, B. L., Shah, A. M., Ballantyne, C. M., Coresh, J., Grams, M. E., Wang, Z., Yu, B., Boerwinkle, E., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19134 · Cited by 68
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi, K. F., Dayoub, E. J., Ross, J. S., Dhruva, S. S., Ahmad, T., & Desai, N. R. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.031 · Cited by 69
GPER-1 and Estrogen Receptor-β Ligands Modulate Aldosterone Synthesis
Caroccia, B., Seccia, T. M., Campos, A. G., Gioco, F., Kuppusamy, M., Ceolotto, G., Guerzoni, E., Simonato, F., Mareso, S., Lenzini, L., et al. (2014) · Endocrinology · doi:10.1210/en.2014-1416 · Cited by 70
Aldosterone and cardiovascular disease: the heart of the matter
He, B. J., & Anderson, M. E. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.09.004 · Cited by 65
Assmus, B., Iwasaki, M., Schachinger, V., Roexe, T., Koyanagi, M., Iekushi, K., Xu, Q., Tonn, T., Seifried, E., Liebner, S., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr388 · Cited by 66
Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes
Gilbert, R. E., Connelly, K. A., Kelly, D. J., Pollock, C. A., & Krum, H. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00540705 · Cited by 70
Giusti, V. C. D., Nolly, M. B., Yeves, A. M., Caldiz, C. I., Villa‐Abrille, M. C., de Cingolani, G. E. C., Ennis, I. L., Cingolani, H. E., & Aiello, E. A. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.176024 · Cited by 66
Rossier, M. F., Lenglet, S., Vetterli, L., Python, M., & Maturana, A. D. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.114223 · Cited by 66
Jurgens, C. Y., Goodlin, S. J., Dolansky, M. A., Ahmed, A., Fonarow, G. C., Boxer, R. S., Arena, R. A., Blank, L., Buck, H. G., Cranmer, K. W., et al. (2015) · Circulation Heart Failure · doi:10.1161/hhf.0000000000000005 · Cited by 80
Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis
Berbenetz, N. M., & Mrkobrada, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0425-x · Cited by 70
Zhou, X., Ono, H., Ono, Y., & Frohlich, E. D. (2004) · American Journal of Nephrology · doi:10.1159/000077396 · Cited by 66
Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease
Gómez-Sánchez, E. P. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200403000-00007 · Cited by 70
Masson, S., Latini, R., Anand, I. S., Barlera, S., Judd, D., Salio, M., Perticone, F., Perini, G., Tognoni, G., & Cohn, J. N. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.02.013 · Cited by 66
Sex and Gender Differences in Cardiovascular Drug Therapy
Seeland, U., & Regitz‐Zagrosek, V. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-30726-3_11 · Cited by 76
Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling
van den Borne, S. W. M., Isobe, S., Zandbergen, H. R., Li, P., Petrov, A. D., Wong, N. D., Fujimoto, S., Fujimoto, A., Løvhaug, D., Smits, J. F. M., et al. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.11.011 · Cited by 65
Self-citationTurgut, F. H., Balogun, R. A., & Abdel‐Rahman, E. M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08611209 · Cited by 74
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.